<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1001244701
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        NINLARO 2.3 mg Hard Capsule
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        IXAZOMIB CITRATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2.3
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule, hard
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        3
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        11947.4
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="HAUPT PHARMA AMAREG GmbH" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            HAUPT PHARMA AMAREG GmbH
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 612]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Abdulrehman Algosaibi G.T.C.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            TAKEDA PHARMA A/S
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01XX50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What NINLARO is</strong><br />NINLARO is a cancer medicine that contains ixazomib, a &lsquo;proteasome inhibitor&rsquo;.<br />NINLARO is used to treat a cancer of the bone marrow called multiple myeloma. Its<br />active substance ixazomib works by blocking the action of proteasomes. These are<br />structures inside the cell that digest proteins and are important for cell survival.<br />Because myeloma cells produce a lot of proteins, blocking the action of proteasomes<br />can kill the cancerous cells.<br /><strong>What NINLARO is used for</strong><br />NINLARO is used to treat adults with multiple myeloma. NINLARO will be given to<br />you together with lenalidomide and dexamethasone, which are other medicines<br />used to treat multiple myeloma.<br /><strong>What multiple myeloma is</strong><br />Multiple myeloma is a cancer of the blood which affects a type of cell, called the<br />plasma cell. A plasma cell is a blood cell that normally produces proteins to fight<br />infections. People with multiple myeloma have cancerous plasma cells, also called<br />myeloma cells, which can damage the bones. Protein produced by myeloma cells<br />can damage the kidneys. Treatment for multiple myeloma involves killing myeloma<br />cells and reducing the symptoms of the disease.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take NINLARO:</strong><br />- if you are allergic to ixazomib or to any of the other any of the other ingredients<br />of this medicine (listed in section 6).<br />If you are uncertain whether the condition above applies to you, talk to your doctor,<br />pharmacist or nurse before taking NINLARO.</p><p><strong>Warnings and precautions</strong><br />Talk to your doctor, pharmacist or nurse before taking NINLARO if:<br />&bull; you have a history of bleeding<br />&bull; you have persistent nausea, vomiting or diarrhoea<br />&bull; you have a history of nerve problems, to include tingling and numbness<br />&bull; you have a history of swelling<br />&bull; you have a persistent rash<br />&bull; you have or have had liver or kidney problems as your dose may have to be<br />adjusted.<br />Your doctor will examine you and you will be monitored closely during treatment.<br />Before starting NINLARO and during treatment, you will have blood tests to check<br />that you have enough blood cells.</p><p><strong>Children and adolescents</strong><br />NINLARO is not recommended for use in children and adolescents aged under<br />18 years.<br /><strong>Other medicines and NINLARO</strong><br />Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might<br />take any other medicines. This includes any medicines obtained without a prescription,<br />such as vitamins or herbal remedies. This is because other medicines can affect<br />the way NINLARO works. In particular, tell your doctor, pharmacist or nurse if you are<br />taking any of the following medicines: carbamazepine, phenytoin, rifampicin and<br />St. John&rsquo;s wort (Hypericum perforatum). These medicines should be avoided as they<br />may reduce the effectiveness of NINLARO.<br /><strong>Pregnancy and breast-feeding</strong><br />NINLARO is not recommended during pregnancy as it may harm your unborn baby.<br />Breast-feeding should be stopped when taking NINLARO.<br />Avoid becoming pregnant or breast feeding while being treated with NINLARO. If<br />you are pregnant or breast-feeding, think you may be pregnant or are planning to<br />have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>If you are a woman of childbearing potential or a man who can father a child,<br />you must use effective contraception during and for 90 days after treatment.<br />Women using hormonal contraceptives should additionally use a barrier method<br />of contraception. Tell doctor right away if you or your partner become pregnant<br />while receiving NINLARO.<br />As NINLARO is given in combination with lenalidomide, you should adhere to the<br />pregnancy prevention programme of lenalidomide because lenalidomide can be<br />harmful to the unborn child.<br />See the package leaflets for lenalidomide and dexamethesone for additional<br />information on pregnancy and breast-feeding<br /><strong>Driving and using machines</strong><br />NINLARO may affect your ability to drive or use machines. You may feel tired and<br />dizzy while taking NINLARO. Do not drive or operate machines if you have these side<br />effects.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>NINLARO must be prescribed to you by a doctor with experience of treating multiple<br />myeloma. Always take this medicine exactly as your doctor or pharmacist has told<br />you.<br />NINLARO is used with lenalidomide (a medicine which affects how your immune<br />system works) and dexamethasone (an anti-inflammatory medicine).<br />NINLARO, lenalidomide and dexamethasone are taken in 4-week treatment cycles.<br />NINLARO is taken once a week (on the same day of the week) for the first 3 weeks of<br />this cycle. The recommended dose is one 4 mg capsule taken by mouth.<br />The recommended dose of lenalidomide is 25 mg taken every day for the first<br />3 weeks of the cycle. The recommended dose of dexamethasone is 40 mg taken<br />once a week on the same day for all 4 weeks of the cycle.</p><p style="margin-left:160px">Dosing schedule: NINLARO taken with lenalidomide and dexamethasone</p><p style="margin-left:160px">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; aTake medicine</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="9" style="vertical-align:top"><p><strong>28-day cycle (a 4-week cycle)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Week 1</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Week 2</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Week 3</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Week 4</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Day 1</p></td><td style="vertical-align:top"><p>Days</p><p>2 to 7</p></td><td style="vertical-align:top"><p>Day 8</p></td><td style="vertical-align:top"><p>Days</p><p>9 to 14</p></td><td style="vertical-align:top"><p>Day</p><p>15</p></td><td style="vertical-align:top"><p>Days</p><p>16 to 21</p></td><td style="vertical-align:top"><p>Day</p><p>22</p></td><td style="vertical-align:top"><p>Days 23</p><p>to 28</p></td></tr><tr><td style="vertical-align:top"><p>NINLARO</p></td><td style="vertical-align:top"><p>a</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>a</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>a</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Lenalidomide</p></td><td style="vertical-align:top"><p>a</p></td><td style="vertical-align:top"><p>aDaily</p></td><td style="vertical-align:top"><p>a</p></td><td style="vertical-align:top"><p>aDaily</p></td><td style="vertical-align:top"><p>a</p></td><td style="vertical-align:top"><p>aDaily</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Dexamethasone</p></td><td style="vertical-align:top"><p>a</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>a</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>a</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>a</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><br />You should read the Package Leaflets of these other medicines for further<br />information on their use and effects.<br />If you have liver or kidney problems, your doctor may prescribe NINLARO capsules<br />containing 3 mg. If you have side effects, your doctor may prescribe NINLARO<br />capsules containing 3 mg or 2.3 mg. The doctor may also adjust the doses of the<br />other medicines.<br /><strong>How and when to take NINLARO</strong><br />&bull; Take NINLARO at least one hour before or at least two hours after food.<br />&bull; Swallow the capsule whole with water. Do not crush, chew or open the capsule.<br />&bull; Do not let the contents of the capsule come into contact with your skin. If the<br />powder accidentally comes into contact with your skin, wash it off thoroughly<br />with soap and water. If the capsule breaks, clean up the powder, taking care that<br />it does not cause dust in the air.<br />If you take more NINLARO than you should<br />If you take more NINLARO than you should, talk to a doctor or go to a hospital<br />straight away. Take the medicine pack with you.<br />Duration of the treatment with NINLARO<br />You should continue treatment until your doctor tells you to stop.<br /><strong>If you forget to take NINLARO</strong><br />If a dose is missed or delayed, you should take the dose as long as the next scheduled<br />dose is more than 3 days or 72 hours away. Do not take a missed dose if it is within<br />3 days or 72 hours of your next scheduled dose.<br />If you vomit after taking a dose, do not take an extra dose. Take the next dose, as<br />normal, when it is due.<br />If you have any further questions on the use of this medicine, ask your doctor or<br />pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>Tell your doctor or pharmacist straight away if you notice any of these following very common serious side effects which may affect more than 1 in 10 people:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low platelet counts (thrombocytopenia) which may increase the risk of nose bleeds and you may easily bruise</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea, vomiting and diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; numbness, tingling or burning of the hands or feet (peripheral neuropathy)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the legs or feet (peripheral oedema)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash that may be itchy and in a few areas or all over the body</p><p><strong>Additionally, tell a doctor immediately if you notice any of these following rare side effects which may affect up to 1 in 1,000 people:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe skin rashes such as red to purple bumps (Sweet&rsquo;s syndrome) or rash with skin peeling and mouth sores (Stevens-Johnson syndrome)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle weakness, loss of feelings of the toes and feet or loss of leg movement (transverse myelitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in vision, changes in mental status, or seizures (posterior reversible encephalopathy syndrome)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rapid death of cancer cells that may cause dizziness, decreased urination, confusion, vomiting, nausea, swelling, shortness of breath, or heart rhythm disturbances (tumour lysis syndrome)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rare blood condition resulting from blood clots that may cause fatigue, fever, bruising, nose bleeds, decreased urination (thrombotic thrombocytopenic purpura)</p><p><strong>Other possible side effects</strong></p><p>Tell your doctor or pharmacist if any of the side effects below become severe.</p><p><strong>Very common side effects may affect more than 1 in 10 people:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; back pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cold-like symptoms (upper respiratory tract infection)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling tired or weak (fatigue)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lowered white blood cells called neutrophils (neutropenia) that may increase the risk of infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; not feeling like eating (decreased appetite)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; irregular heart rate (arrhythmia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vision conditions including blurred vision, dry eye and pink eye (conjunctivitis)</p><p><strong>Common side effects may affect up to 1 in 10 people:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reactivation of the chicken pox virus (shingles) that can cause a skin rash and pain (herpes zoster)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lowered blood pressure (hypotension)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath or persistent coughing or wheezing (heart failure)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; yellow discoloration of eyes and skin (jaundice which could be a symptom of liver impairment)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low levels of potassium in the blood (hypokalaemia)</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly to the national pharmacovigilance and drug safety centre (NPC) By reporting side effects you can help provide more information on the safety of this medicine</p><p><strong>To report any side effect(s):</strong></p><p><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia:</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p><strong>The National Pharmacovigilance and Drug Safety Centre (NPC)</strong></p><p>Fax: +966-11-205-7662</p><p>Call NPC at +966-11-2038222</p><p>Exts: 2317-2356-2353-2354-2334-2340.</p><p>Toll free phone: 8002490000 E-mail: npc.drug@sfda.gov.sa Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Other GCC States:</em></strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p>Please contact the relevant competent authority.</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the wallet and carton after EXP. The expiry date refers to the last day of that month.</p><p>Do not store above 30&deg;C. Do not freeze.</p><p>Store in the original package in order to protect from moisture. Do not remove the capsule until you need to take a dose.</p><p>Do not use this medicine if you notice any damage or signs of tampering to medicine packaging.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>NINLARO 2.3 mg hard capsule:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each hard capsule contains ixazomib citrate equivalent to 2.3 mg of ixazomib. Other ingredients include microcrystalline cellulose, magnesium stearate and talc.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The capsule shell contains: gelatin, titanium dioxide (E171) and red iron oxide (E172)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The printing ink contains: shellac, propylene glycol, potassium hydroxide, and black iron oxide (E172).</p><p><strong>NINLARO 3 mg hard capsule:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each hard capsule contains ixazomib citrate equivalent to 3 mg of ixazomib. Other ingredients include microcrystalline cellulose, magnesium stearate and talc.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The capsule shell contains: gelatin, titanium dioxide (E171) and black iron oxide (E172)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The printing ink contains: shellac, propylene glycol, potassium hydroxide, and black iron oxide (E172).</p><p><strong>NINLARO 4 mg hard capsule:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each hard capsule contains ixazomib citrate equivalent to 4 mg of ixazomib. Other ingredients include microcrystalline cellulose, magnesium stearate and talc.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The capsule shell contains: gelatin, titanium dioxide (E171), yellow iron oxide (E172) and red iron oxide (E172)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The printing ink contains: shellac, propylene glycol, potassium hydroxide, and black iron oxide (E172).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                NINLARO 2.3 mg hard capsule: Light pink, size 4, marked “Takeda” on the cap and “2.3 mg” on the body with black ink.

NINLARO 3 mg hard capsule: Light grey, size 4, marked “Takeda” on the cap and “3 mg” on the body with black ink.

NINLARO 4 mg hard capsule: Light orange, size 3, marked “Takeda” on the cap and “4 mg” on the body with black ink.

Each pack contains three single cartons, each containing a blister sealed inside a wallet. Each blister contains one capsule.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder</strong></p><p>Takeda Pharma A/S Dybendal Alle 10</p><p>2630 Taastrup Denmark</p><p><strong>Manufactured by:</strong></p><p>Haupt Pharma Amareg GmbH Donaustaufer St.378</p><p>93055 Regensburg Germany</p><p><strong>Batch Released by:</strong></p><p>Takeda Pharma A/S Dybendal Alle 10</p><p>2630 Taastrup Denmark</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaﬂet was last revised in November 2016
Other sources of information


            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>نینلارو هو دواء للسرطان الذي یحتوي على إك ا ززومیب ، مثبط البروتیزوم. ویستخدم نینلارو في علاج سرطان نخاع<br />العظام المعروف باسم الورم النقوي المتعدد حیث تعمل مادته الفعالة إك ا ززومیب من خلال إعاقة عمل جسیمات البروتیز وم، وهي تركیبات داخل الخلیة تعمل على هضم البر وتینات، وضروریة لبقاء الخلیة. ویمكن لعرقلة عمل جسیمات البروتیزوم<br />أن یقتل الخلایا السرطانیة لأن خلایا الورم النقوي تنتج الكثیر من البروتینات.</p><p><strong>فیم یستخدم نینلارو</strong><br />یستخدم نینلارو لعلاج البالغین ممن یعانون من الورم النقوي المتعدد، ویعطى جنب اً إلى جنب مع لینالیدومید ودیكسامیثازون وهي أدویة أخرى مستخدمة لعلاج الورم النقوي المتعدد.<br /><strong>ما هو الورم النقوي المتعدد</strong><br />الورم النقوي المتعدد هو سرطان الدم الذي یؤثر على نوع من الخلایا تسمى خلایا البلازما، وخلیة البلازما هي خلیة من خلایا الدم تنتج البروتینات بصورة طبیعیة لمكافحة العدوى، فالأشخاص المصابون بالورم النقوي المتعدد لدیهم خلایا<br />بلازما سرطانیة، وتسمى أیض اً خلایا الورم النقوي والتي تستطیع تدمیر العظام، ویمكن للبروتین الذي تنتجه خلایا الورم النقوي أن یدمر الكلیتین، وتشمل وظائف علاج الورم النقوي المتعدد قتل خلایا الورم النقوي، والحد من أع ا رض المرض.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا تتناول دواء نینلارو في الحالات التالیة:</strong><br />.( - إذا كنت تعاني من حساسیة للإك ا ززومیب أو لأي مكون من المكونات الأخرى لهذا الدواء (المدرجة في القسم 6<br />إذا كنت غیر متأكد من انطباق الشرط المذكور أعلاه علیك؛ ا رجع طبیبك أو الصیدلي او الممرضة قبل تناول دواء نینلارو.<br /><strong>المحاذیر والاحتیاطات:</strong><br />ا رجع طبیبك أو الصیدلي أو الممرضة قبل تناول دواء نینلارو في الحالات التالیة:<br />&bull; إذا كان لدیك تاریخ من نزف الدم.<br />&bull; إذا كنت تعاني من غثیان مستمر أو قيء أو إسهال.<br />&bull; كان لدیك تاریخ من المشكلات العصبیة تشمل الوخزو التنمیل.<br />&bull; كان لدیك تاریخ من التورم.<br />&bull; كنت تعاني من طفح جلدي مستمر.<br />&bull; كان لدیك مشكلات في الكبد أو الكلیتین، أو كنت تعاني من مشكلات فیهما، حیث قد یستوجب الأمر تعدیل جرعتك.<br />سیقوم الطبیب بفحصك، وسیجرى رصد حالتك عن كثب خلال فترة العلاج. وقبل البدء في تناول نینلارو وخلال فترة العلاج،<br />ستخضع لإج ا رء اختبا ا رت الدم للتحقق أن لدیك ما یكفي من خلایا الدم.</p><p><strong>الأطفال والمراهقين</strong></p><p>لا ینصح باستخدام نینلارو في الأطفال والم ا رهقین ممن تقل أعمارهم عن 18 عاما</p><p><strong>نینلارو والأدویة الأخرى</strong><br />إذا كنت تتعاطى أدویة أخرى أو قد تناولت مؤخر ا أي منها؛ أبلغ طیبك أو الصیدلي أو الممرضة بذلك، ویشمل هذا أي أدویة<br />یتم تناولها دون وصفة طبیة، مثل الفیتامینات أو العلاجات العشبیة، وذلك لأن الأدویة الأخرى یمكن أن تؤثر على الطریقة<br />التي یعمل بها دواء نینلارو. أبلغ طیبك أو الصیدلي أو المرضة إذا كنت تتعاطى أی اً من الأدویة التالیة على وجه الخصوص:<br />كاربامازیبین، و فینیتوین، و ریفامبیسین ونبتة سانت جون (هایبیریكم بیرف ا رتم)، فینبغي تجنب تلك الأدویة لأنها قد تقلل من فاعلیة<br />نینلارو.<br /><strong>الحمل والرضاعة الطبيعية</strong><br />لا ینصح بتناول نینلارو خلال فترة الحمل لأنه قد یضرّ بالجنین، ویجب إیقاف الرضاعة الطبیعیة عند تناول دواء نینلارو.<br />تجنبي الحمل والرضاعة الطبیعیة أثناء تناول دواء نینلارو، وإذا كنت حاملا أو ترضعین رضاعة طبیعیة، أو تعتقدین بأنك<br />ربما تكونین حاملا ، أو تعتزمین الإنجاب، اطلبي من طبیبك أو الصیدلي النصیحة قبل تناول هذا الدواء.<br />وإذا كنت ام أ رة لدیك القدرة على حمل وإنجاب طفل أو إذا كنت رجلا قاد ا رً على الإنجاب؛ ینبغي أن تستخدم وسائل منع الحمل<br />الفعالة خلال فترة العلاج ولمدة 90 یوم بعد العلاج، وینبغي على السیدات اللواتي یستخدمن وسائل منع الحمل الهرمونیة<br />استخدام وسیلة عازلة لمنع الحمل. أخبر طبیبك على الفور إذا أصبحت أنت أو شریكك حاملا أثناء التداوي بنینلارو.<br />وبما أن دواء نینلارو یعطى جنباً إلى جنب مع اللینالیدومید؛ ینبغي أن تلتزمي ببرنامج اللینالیدومید للوقایة من حدوث الحمل،<br />حیث یمكن للینالیدومید أن یلحق الضرر بالجنین.</p><p>طالع النشرات&nbsp;&nbsp;الداخلیة للینالیدومید والدیكسامیثازون للحصول على المزید من المعلومات حول الحمل والرضاعة الطبیعیة.<br /><strong>القیادة واستخدام الآلات</strong><br />قد یؤثر نینلارو على قدرتك على القیادة أو استخدام الآلات. قد تشعر بالتعب والدوار عندما تتناول دواء نینلارو؛ فلا تقود<br />السیارة أو تشغل الآلات إذا كان لدیك تلك الأع ا رض الجانبیة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ینبغي أن یوصف دواء نینلارو من قبل طبیب لدیه خبرة في علاج الورم النقوي المتعدد. تناول هذا الدواء تمام اً كما أخبرك<br />طبیبك أو الصیدلي.<br />یستخدم دواء نینلارو مع اللینالیدومید (دواء یؤثر على كیفیة عمل جهاز المناعة لدیك)، والدیكسامیثازون (دواء مضاد<br />للالتهابات).<br />ویجرى تناول دواء نینلارو واللینالیدومید والدیكسامیثازون في دو ا رت علاجیة مدتها 4 أسابیع، یؤخذ نینلارو مرة واحدة أسبوعیا<br />(في نفس الیوم من الأسبوع) خلال الأسابیع الثلاثة الأولى من هذه الدورة، والجرعة الموصى بها هي كبسولة 4 ملجم تؤخذ عن<br />طریق الفم.<br />الجرعة الموصى بها من اللینالیدومید هي 25 م لجم،و تؤخذ یومیا خلال الأسابیع الثلاثة الأولى من الدورة. و الجرعة الموصى<br />بها من الدیكسامیثازون هي 40 م لجم،و تؤخذ مرة واحدة أسبوعیا في نفس الیوم من الأسبوع خلال مدة الدورة التي تبلغ 4<br />أسابیع.</p><p>اﻟﺠدول اﻟزﻤﻨﻲ ﻟﺘﻨﺎول اﻟﺠرﻋﺎت: ﯿؤﺨذ دواء ﻨﯿﻨﻼرو ﻤﻊ اﻟﻠﯿﻨﺎﻟﯿدوﻤﯿد واﻟدﯿﻛﺴﺎﻤﯿﺜﺎزون</p><p dir="RTL">a&nbsp;&nbsp;اﻟدواء اﻟذي ﯿﺘم ﺘﻨﺎوﻟﻪ</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="9" style="vertical-align:top"><p dir="RTL"><strong>دورة ﻤدﺘﻬﺎ</strong><strong> </strong><strong>28</strong><strong>&nbsp; ﯿوم&nbsp; </strong><strong>)</strong><strong>دورة</strong><strong> </strong><strong>4</strong><strong>&nbsp; أﺴﺎﺒﯿﻊ</strong><strong>(</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p dir="RTL"><strong>اﻷﺴﺒوع</strong><strong> </strong><strong>4</strong></p></td><td colspan="2" style="vertical-align:top"><p dir="RTL"><strong>اﻷﺴﺒوع</strong><strong> </strong><strong>3</strong></p></td><td colspan="2" style="vertical-align:top"><p dir="RTL"><strong>اﻷﺴﺒوع</strong><strong> </strong><strong>2</strong></p></td><td colspan="2" style="vertical-align:top"><p dir="RTL"><strong>اﻷﺴﺒوع</strong><strong> </strong><strong>1</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اﻟﯿوم ﻤن 23</p><p dir="RTL">إﻟﻰ 28</p></td><td style="vertical-align:top"><p dir="RTL">اﻟﯿوم</p><p>22</p></td><td style="vertical-align:top"><p dir="RTL">اﻷﯿﺎم ﻤن</p><p>21 إﻟﻰ 16</p></td><td style="vertical-align:top"><p dir="RTL">اﻟﯿوم 15</p></td><td style="vertical-align:top"><p dir="RTL">اﻷﯿﺎم ﻤن 9</p><p dir="RTL">إﻟﻰ 14</p></td><td style="vertical-align:top"><p dir="RTL">اﻟﯿوم 8</p></td><td style="vertical-align:top"><p dir="RTL">اﻷﯿﺎم ﻤن 2</p><p dir="RTL">إﻟﻰ 7</p></td><td style="vertical-align:top"><p dir="RTL">اﻟﯿوم 1</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>a</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>a</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>a</p></td><td style="vertical-align:top"><p dir="RTL">ﻨﯿﻨﻼرو</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">a ﯿوﻤﯿﺎ</p></td><td style="vertical-align:top"><p>a</p></td><td style="vertical-align:top"><p dir="RTL">a ﯿوﻤﯿﺎ</p></td><td style="vertical-align:top"><p>a</p></td><td style="vertical-align:top"><p dir="RTL">a ﯿوﻤﯿﺎ</p></td><td style="vertical-align:top"><p>a</p></td><td style="vertical-align:top"><p dir="RTL">اﻟﻠﯿﻨﺎﻟﯿدوﻤﯿد</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>a</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>a</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>a</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>a</p></td><td style="vertical-align:top"><p dir="RTL">اﻟدﯿﻛﺴﺎﻤﯿﺜﺎزون</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">یتعیّن علیك ق ا رءة النش ا رت الداخلیة للأدویة الأخرى طلباً لمزید من المعلومات بشأن استخداماتها وتأثی ا رتها.<br />إذا كنت تعاني من مشكلات في الكبد أو الكلیتین؛ قد یصف لك طبیبك كبسولات نینلارو تحتوي على 3 ملجم.<br />إذا كان لدیك أع ا رض اً جانبیة؛ سیصف لك طبیبك كبسولات نینلارو تحتوي على 3 ملجم أو 2.3 ملجم، وقد یضبط الطبیب<br />أیضا جرعات الأدویة الأخرى.</p><p dir="RTL"><strong>كیف ومتى تأخذ دواء نینلارو</strong><br />&bull; تناول نینلارو قبل تناول الطعام بساعة واحدة أو بعد تناوله بساعتین على الأقل.<br />&bull; ابتلع الكبسولة مع الماء، ولا تسحق أو تمضغ او تفتح الكبسولة.</p><p dir="RTL">&bull; لا تدع محتویات الكبسولة تتلامس مع بشرتك، وإذا لامس مسحوق الكبسولة بشرتك عن طریق الخطأ؛ اغسله جید اً<br />بالماء والصابون، وإذا انكسرت الكبسولة؛ نظف المسحوق مع الحرص على ألا یتطایر مسبب اً غبا ا رً في الهواء.</p><p dir="RTL"><strong>إذا تناولت أكثر مما ینبغي من نینلارو</strong><br />إذا تناولت أكثر مما ینبغي من نینلارو؛ أبلغ الطبیب أو اذهب إلى المستشفى على الفور، وخذ عبوة الدواء معك.<br /><strong>مدة العلاج باستخدام نینلارو</strong><br />ینبغي أن تستمر في العلاج حتى یطلب منك الطبیب التوقف عن تناوله.<br /><strong>إذا نسیت تناول نینلارو</strong><br />إذا تأخرت في تناول الجرعة أو نسیت تناولها؛ ینبغي أن تأخذ الجرعة طالما أن موعد تناول الجرعة المحددة التالیة یقع بعد<br />أكثر من 3 أیام أو 72 ساعة، ولا تتناول الجرعة التي فاتك تناولها إذا كانت خلال 3 أیام أو 72 ساعة من جرعتك القادمة.<br />إذا تقیأت بعد تناول جرعة من الجرعات؛ لا تتناول جرعة إضافیة، وتناول الجرعة التالیة كالمعتاد عندما یحین موعدها.<br />إذا كان لدیك أي استفسا ا رت إضافیة؛ اسأل طبیبك أو الصیدلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>قد یسبب هذا الدواء آثا ا رً جانبیة مثل جمیع الأدویة، وإن لم یعاني منها الجمیع.<br /><strong>وإذا لاحظت أیا من تلك الآثار الجانبیة الخطیرة التالیة والشائعة جد اً، والتي قد تصیب 1 بین كل 10 أشخاص؛ أبلغ طبیبك<br />أو الصیدلي على الفور:</strong><br />&bull; انخفاض أعداد الصفائح الدمویة (قلة الصفیحات) والتي قد تزید من خطر نزیف الأنف، وقد تصاب بالكدمات<br />بسهولة.<br />&bull; الغثیان والقيء والإسهال.<br />&bull; تنمیل أو وخز أو تحرق الیدین أو القدمین (الاعتلال العصبي المحیطي).<br />&bull; تورم الساقین أو القدمین (الوذمة المحیطیة).<br />&bull; الطفح الجلدي والذي قد یكون مصحوب اً بحكة في مناطق قلیلة أو في جمیع أج ا زء الجسم.<br /><strong>وبالإضافة إلى ذلك، أبلغ طبیبك على الفور إذا لاحظت أی اً من الآثار الجانبیة التالیة، والنادر حدوثها، والتي قد تصیب 1<br />بین كل 1000 شخص:</strong><br />&bull; الطفح الجلدي الخطیر مثل الآفات الحمامیة الحم ا رء إلى الأرجوانیة (متلازمة سویت)، أو حدوث الطفح الجلدي مع<br />تقشر الجلد وتقرحات الفم (متلازمة ستفنس جونسون).<br />&bull; ضعف العضلات، وفقدان الإحساس في أصابع القدم والقدمین، أو فقدان حركة الساق (التهاب النخاع المستعرض).</p><p>&bull; تغيرات&nbsp;في الرؤیة، وتغيرات في الحالة النفسیة، أو نوبات صرع (متلازمة الاعتلال الدماغي الخلفي المتقلب).<br />&bull; الموت السریع للخلایا السرطانیة مما قد یسبب دوخة، أو نقص التبول، أو الارتباك، أو القيء، أو الغثیان، والتورم، أو<br />ضیق التنفس، أو اضط ا رب نبضات القلب (متلازمة انحلال الورم).<br />&bull; حالة نادرة للدم تنتج من جلطات دمویة قد تسبب الإجهاد، والحمى، والكدمات، ونزیف الأنف، ونقص التبول (الفرفریة<br />قلیلة الصفیحات الخثاریة).</p><p><strong>الآثار الجانبیة المحتملة الأخرى</strong><br />أخبر طبیبك أو الصیدلي إذا اشتدت علیك أي من الآثار الجانبیة التالیة:<br /><strong>الآثار الجانبیة الشائعة جد اً والتي قد تؤثر على شخص واحد بین كل 10 أشخاص:</strong><br />&bull; الإمساك.<br />&bull; آلام الظهر.<br />&bull; الأع ا رض المشابهة للبرد (عدوى الجاز التنفسي العلوي).<br />&bull; الشعور بالإرهاق او الضعف (الإجهاد).<br />&bull; انخفاض خلایا الدم البیضاء التي تسمى العدلات (قلة العدلات) والتي قد تزید من خطورة العدوى.<br />&bull; عدم الشعور بالرغبة في تناول الطعام (قلة الشهیة).<br />&bull; عدم انتظام معدل ضربات القلب (اضط ا رب ضربات القلب).<br />&bull; حالات الرؤیة بما في ذلك ضبابیة الرؤیة، ومتلازمة جفاف العین، والعین القرنفلیة (التهاب الملتحمة).<br /><strong>الآثار الجانبیة الشائعة والتي قد تؤثر على شخص واحد بین كل 10 أشخاص:</strong><br />&bull; إعادة تنشیط فیروس جدري الدجاج (القوباء) والذي یمكن أن یسبب طفح جلدي وألم (هربسٌ نطاقي).<br />&bull; انخفاض ضغط الدم.<br />&bull; ضیق التنفس أو السعال المستمر أو التنفس مع صوت صفیر (قصور القلب).<br />&bull; تغیر لون الجلد والعینین إلى اللون الأصفر (الیرقان الذي یمكن أن یكون أحد أع ا رض الاعتلال الكبدي).<br />&bull; انخفاض مستویات البوتاسیوم في الدم (نقص البوتاسیوم في الدم).<br /><strong>الإبلاغ عن الأثار الجانبیة</strong><br />إذا أصبت بأي من الآثار الجانبیة، أبلغ طبیبك أو الصیدلي أو الممرضة، ویشمل ذلك أي آثار جانبیة محتملة غیر مدرجة في<br />هذه النشرة، یمكنك المساعدة في توفیر المزید من المعلومات حول سلامة هذا الدواء عن طریق الإبلاغ عن الآثار الجانبیة.</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احتفظ بهذا الدواء بعید اً عن مرآىو متناول الأطفال.</p><p>لا تستخدم هذا الدواء بعد انقضاء تاریخ صلاحیته المدون على العبوة وعلبة الكرتون بعد عبارة&nbsp;&nbsp;ویشیر تاریخ انتهاء<br />الصلاحیة إلى الیوم الأخیر من هذا الشهر.<br />لا تحفظ الدواء عند درجة ح ا ررة تزید عن 30 درجة مئویة، ولا تجمده.<br />احفظ الدواء في عبوته الأصلیة لحمایته من الرطوبة.<br />لا تنزع الكبسولة إلا عند تناول جرعة.<br />لا تستخدم هذا الدواء إذا لاحظت أي تلف بعبوة الدواء أو أي علامة تدل على العبث بها.<br />لا تتخلص من أي أدویة عبر إلقائها في میاه الصرف الصحي أو النفایات المنزلیة، اسأل الصیدلي عن كیفیة التخلص من<br />الأدویة التي لم تعد بحاجة إلى استخدامها. إن من شأن هذه التدابیر المساعدة في حمایة البیئة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>كبسولات نینلارو الصلبة 2.3 ملجم</strong><br />&bull; تحتوي كل كبسولة صلبة على ست ا رت إك ا ززومیب ما یعادل 2.3 ملجم من الإك ا ززومیب ، وتشمل المكونات الأخرى<br />على سلیولوز دقیق البللو ا رت، وستی ا رت الماغنسیوم، وفلز التلك.<br />.(E وأكسید الحدید الأحمر ( 172 ،(E &bull; تحتوي قشرة الكبسولة على: الجیلاتین، وثاني أكسید التیتانیوم ( 171</p><p>&bull; یحتوي حبر الطباعة على: صمغ اللك، والبروبیلین غلیكول، وهیدروكسید البوتاسیوم، وأكسید الحدید الأسود<br />.(E172)<br /><strong>كبسولات نینلارو الصلبة 3 ملجم</strong><br />&bull; تحتوي كل كبسولة صلبة على ست ا رت إك ا ززومیب ما یعادل 3 ملجم من الإك ا ززومیب ، وتشمل المكونات الأخرى على<br />سلیولوز دقیق البللو ا رت، وستی ا رت الماغنسیوم، وفلز التلك.<br />.(E وأكسید الحدید الأحمر ( 172 ،(E &bull; تحتوي قشرة الكبسولة على: الجیلاتین، وثاني أكسید التیتانیوم ( 171<br />&bull; یحتوي حبر الطباعة على: صمغ اللك، والبروبیلین غلیكول، وهیدروكسید البوتاسیوم، وأكسید الحدید الأسود<br />.(E172)<br /><strong>كبسولات نینلارو الصلبة 4 ملجم</strong><br />&bull; تحتوي كل كبسولة صلبة على ست ا رت إك ا ززومیب ما یعادل 4 ملجم من الإك ا ززومیب ، وتشمل المكونات الأخرى على<br />سلیولوز دقیق البللو ا رت، وستی ا رت الماغنسیوم، وفلز التلك.<br />وأكسید ،(E وأكسید الحدید الأصفر ( 172 ،(E &bull; تحتوي قشرة الكبسولة على: الجیلاتین، وثاني أكسید التیتانیوم ( 171<br />.(E الحدید الأحمر ( 172<br />&bull; یحتوي حبر الطباعة على: صمغ اللك، والبروبیلین غلیكول، وهیدروكسید البوتاسیوم، وأكسید الحدید الأسود<br />.(E172)</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>على الغطاء، ومدوّن على جسم &rdquo;Takeda&ldquo; كبسولات نینلارو الصلبة 2.3 ملجم : وردي فاتح ، حج م 4 ، وتحم ل علام ة<br />الكبسولة 2.3 ملجم بالحبر الأسود.<br />على الغطاء، ومدوّن على جسم الكبسولة &rdquo;Takeda&ldquo; كبسولات نینلارو الصلبة 3 ملجم: رمادي فاتح، حجم 4، وتحمل علامة<br />3 ملجم بالحبر الأسود.<br />على الغطاء، ومدوّن على جسم الكبسولة &rdquo;Takeda&ldquo; كبسولات نینلارو الصلبة 4 ملجم: برتقالي فاتح، حجم 3، وتحمل علامة<br />4 ملجم بالحبر الأسود.<br />تحتوي كل عبوة على ثلاث علب كرتون مفردة، و تحتوي كل منها على حویصلة محكمة الإغلاق داخل حافظة، تحتوي كل<br />حویصلة على كبسولة واحدة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>صاحب رخصة التسویق:</strong><br />Takeda Pharma A/S<br />Dybendal Alle 10<br />2630 Taastrup<br />Denmark<br /><strong>الجھة المصنعة:</strong><br />Haupt Pharma Amareg GmbH<br />Donaustaufer St.378<br />Regensburg, Germany 93055<br /><strong>موقع الإفراج النھائي عن التشغیلة الدوائیة</strong><br />Takeda Pharma A/S<br />Dybendal Alle 10<br />2630 Taastrup, Denmark</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            جرى التنقیح الأخیر لھذه النشرة في یولیو 2017
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                NINLARO 2.3 mg hard capsules
NINLARO 3 mg hard capsules
NINLARO 4 mg hard capsules
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                NINLARO 2.3 mg hard capsules
Each capsule contains 2.3 mg of ixazomib (as 3.3 mg of ixazomib citrate)
NINLARO 3 mg hard capsules
Each capsule contains 3 mg of ixazomib (as 4.3 mg of ixazomib citrate)
NINLARO 4 mg hard capsules
Each capsule contains 4 mg of ixazomib (as 5.7 mg of ixazomib citrate)
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hard capsule.
NINLARO 2.3 mg hard capsules
Light pink, size 4 hard gelatin capsule, marked “Takeda” on the cap and “2.3 mg” on the body with
black ink.
NINLARO 3 mg hard capsules
Light grey, size 4 hard gelatin capsule, marked “Takeda” on the cap and “3 mg” on the body with
black ink.
NINLARO 4 mg hard capsules
Light orange, size 3 hard gelatin capsule, marked “Takeda” on the cap and “4 mg” on the body with
black ink.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NINLARO in combination with lenalidomide and dexamethasone is indicated for the treatment of<br />adult patients with multiple myeloma who have received at least one prior therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment must be initiated and monitored under the supervision of a physician experienced in the<br />management of multiple myeloma.</p><p>Posology<br />The recommended starting dose of NINLARO is 4 mg administered orally once a week on Days 1, 8,<br />and 15 of a 28-day treatment cycle.<br />The recommended starting dose of lenalidomide is 25 mg administered daily on Days 1 to 21 of a<br />28-day treatment cycle.<br />The recommended starting dose of dexamethasone is 40 mg administered on Days 1, 8, 15, and 22 of a<br />28-day treatment cycle.</p><p>Dosing schedule: NINLARO taken with lenalidomide and dexamethasone</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="9" style="vertical-align:top"><p><strong>28-day cycle (a 4-week cycle)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Week 1</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Week 2</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Week 3</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Week 4</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Day 1</p></td><td style="vertical-align:top"><p>Days</p><p>2 to 7</p></td><td style="vertical-align:top"><p>Day 8</p></td><td style="vertical-align:top"><p>Days</p><p>9 to 14</p></td><td style="vertical-align:top"><p>Day</p><p>15</p></td><td style="vertical-align:top"><p>Days</p><p>16 to 21</p></td><td style="vertical-align:top"><p>Day</p><p>22</p></td><td style="vertical-align:top"><p>Days 23</p><p>to 28</p></td></tr><tr><td style="vertical-align:top"><p>NINLARO</p></td><td style="vertical-align:top"><p>a</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>a</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>a</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Lenalidomide</p></td><td style="vertical-align:top"><p>a</p></td><td style="vertical-align:top"><p>aDaily</p></td><td style="vertical-align:top"><p>a</p></td><td style="vertical-align:top"><p>aDaily</p></td><td style="vertical-align:top"><p>a</p></td><td style="vertical-align:top"><p>aDaily</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Dexamethasone</p></td><td style="vertical-align:top"><p>a</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>a</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>a</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>a</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>a= intake of medicinal product</p><p>For additional information regarding lenalidomide and dexamethasone, refer to the Summary of Product Characteristics (SmPC) for these medicinal products.</p><p>Prior to initiating a new cycle of therapy:</p><p>&middot;&nbsp;&nbsp; Absolute neutrophil count should be &ge; 1,000/mm<sup>3</sup></p><p>&middot;&nbsp;&nbsp; Platelet count should be &ge; 75,000/mm<sup>3</sup></p><p>&middot;&nbsp;&nbsp; Non-haematologic toxicities should, at the physician&rsquo;s discretion, generally be recovered to patient&rsquo;s baseline condition or &le; Grade 1</p><p>Treatment should be continued until disease progression or unacceptable toxicity. Treatment with NINLARO in combination with lenalidomide and dexamethasone for longer than 24 cycles should be based on an individual benefit risk assessment, as the data on the tolerability and toxicity beyond</p><p>24 cycles are limited (see section 5.1).</p><p><em><u>Delayed or missed doses</u></em></p><p>In the event that a NINLARO dose is delayed or missed, the dose should be taken only if the next scheduled dose is &ge; 72 hours away. A missed dose should not be taken within 72 hours of the next scheduled dose. A double dose should not be taken to make up for a missed dose.</p><p>If a patient vomits after taking a dose, the patient should not repeat the dose but should resume dosing at the time of the next scheduled dose.</p><p><em><u>Dose modifications</u></em></p><p>The NINLARO dose reduction steps are presented in Table 1 and the dose modification guidelines are provided in Table 2.</p><p>Table 1: NINLARO dose reduction steps</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Recommended starting dose*</p></td><td style="vertical-align:top"><p>First reduction to</p></td><td style="vertical-align:top"><p>Second reduction to</p></td><td rowspan="2" style="vertical-align:top"><p>Discontinue</p></td></tr><tr><td style="vertical-align:top"><p>4 mg</p></td><td style="vertical-align:top"><p>3 mg</p></td><td style="vertical-align:top"><p>2.3 mg</p></td></tr></tbody></table><p>*Recommended reduced dose of 3 mg in the presence of moderate or severe hepatic impairment, severe renal impairment or end-stage renal disease (ESRD) requiring dialysis.</p><p>An alternating dose modification approach is recommended for NINLARO and lenalidomide for overlapping toxicities of thrombocytopenia, neutropenia and rash. For these toxicities, the first dose modification step is to withhold/reduce lenalidomide. Refer to the lenalidomide SmPC, section 4.2 for the dose reduction steps for these toxicities.</p><p>&nbsp;</p><p><strong>Table 2: Dose modifications guidelines for NINLARO in combination with lenalidomide and dexamethasone</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Haematological toxicities</strong></p></td><td style="vertical-align:top"><p><strong>Recommended actions</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Thrombocytopenia (platelet count)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Platelet count &lt; 30,000/mm<sup>3</sup></p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp; Withhold NINLARO and lenalidomide until platelet count</p><p>&ge; 30,000/mm<sup>3</sup>.</p><p>&middot;&nbsp;&nbsp; Following recovery, resume lenalidomide at the next lower dose according to its SmPC and resume NINLARO at its most recent dose.</p><p>&middot;&nbsp;&nbsp; If platelet count falls to &lt; 30,000/mm<sup>3</sup> again, withhold NINLARO and lenalidomide until platelet count</p><p>&ge; 30,000/mm<sup>3</sup>.</p><p>&middot;&nbsp;&nbsp; Following recovery, resume NINLARO at the next lower dose and resume lenalidomide at its most recent dose.*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Neutropenia (absolute neutrophil count)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Absolute neutrophil count</p><p>&lt; 500/mm<sup>3</sup></p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Withhold NINLARO and lenalidomide until absolute neutrophil count is &ge; 500/mm<sup>3</sup>. Consider adding G-CSF as per clinical guidelines.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Following recovery, resume lenalidomide at the next lower dose according to its prescribing information and resume NINLARO at its most recent dose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; If absolute neutrophil count falls to &lt; 500/mm<sup>3</sup> again,&nbsp;withhold NINLARO and lenalidomide until absolute neutrophil count is &ge; 500/mm<sup>3</sup>.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Following recovery, resume NINLARO at the next lower dose and resume lenalidomide at its most recent dose.*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Non-haematological toxicities</strong></p></td><td style="vertical-align:top"><p><strong>Recommended actions</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Rash</strong></p></td></tr><tr><td style="vertical-align:top"><p>Grade<sup>&dagger;</sup> 2 or 3</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp; Withhold lenalidomide until rash recovers to &le; Grade 1.</p><p>&middot;&nbsp;&nbsp; Following recovery, resume lenalidomide at the next lower dose according to its SmPC.</p><p>&middot;&nbsp;&nbsp; If Grade 2 or 3 rash occurs again, withhold NINLARO and lenalidomide until rash recovers to &le; Grade 1.</p><p>&middot;&nbsp;&nbsp; Following recovery, resume NINLARO at the next lower dose and resume lenalidomide at its most recent dose.*</p></td></tr><tr><td style="vertical-align:top"><p>Grade 4</p></td><td style="vertical-align:top"><p>Discontinue treatment regimen.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Peripheral neuropathy</strong></p></td></tr><tr><td style="vertical-align:top"><p>Grade 1 peripheral neuropathy with pain or Grade 2 peripheral neuropathy</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp; Withhold NINLARO until peripheral neuropathy recovers to</p><p>&le; Grade 1 without pain or patient&#39;s baseline.</p><p>&middot;&nbsp;&nbsp; Following recovery, resume NINLARO at its most recent dose.</p></td></tr><tr><td style="vertical-align:top"><p>Grade 2 peripheral neuropathy with pain or Grade 3 peripheral neuropathy</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp; Withhold NINLARO. Toxicities should, at the physician&rsquo;s discretion, generally recover to patient&rsquo;s baseline condition or &le; Grade 1 prior to resuming NINLARO.</p><p>&middot;&nbsp;&nbsp; Following recovery, resume NINLARO at the next lower dose.</p></td></tr><tr><td style="vertical-align:top"><p>Grade 4 peripheral neuropathy</p></td><td style="vertical-align:top"><p>Discontinue treatment regimen.</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Table 2: Dose modifications guidelines for NINLARO in combination with lenalidomide and dexamethasone</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Other non-haematological toxicities</strong></p></td></tr><tr><td style="vertical-align:top"><p>Other Grade 3 or 4</p><p>non-hematological toxicities</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Withhold NINLARO. Toxicities should, at the physician&rsquo;s discretion, generally recover to patient&rsquo;s baseline condition or at most Grade 1 prior to resuming NINLARO.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; If attributable to NINLARO, resume NINLARO at the next lower dose following recovery.</p></td></tr></tbody></table><p>*For additional occurrences, alternate dose modification of lenalidomide and NINLARO</p><p>&dagger;Grading based on National Cancer Institute Common Terminology Criteria (CTCAE) Version 4.03</p><p>&nbsp;</p><p><em><u>Concomitant medicinal products</u></em></p><p>Antiviral prophylaxis should be considered in patients being treated with NINLARO to decrease the risk of herpes zoster reactivation. Patients included in studies with NINLARO who received antiviral prophylaxis had a lower incidence of herpes zoster infection compared to patients who did not receive prophylaxis.</p><p>Thromboprophylaxis is recommended in patients being treated with NINLARO in combination with lenalidomide and dexamethasone, and should be based on an assessment of the patient&rsquo;s underlying risks and clinical status.</p><p>For other concomitant medicinal products that may be required, refer to the current lenalidomide and dexamethasone SmPC.</p><p>&nbsp;</p><p><em><u>Special patient populations</u></em></p><p><u><strong><em>Elderly</em></strong></u></p><p>No dose adjustment of NINLARO is required for patients over 65 years of age.</p><p>Discontinuations in patients &gt; 75 years of age were reported in 13 patients (28%) in the NINLARO regimen and 10 patients (16%) in the placebo regimen. Cardiac arrhythmias in patients &gt; 75 years of age were observed in 10 patients (21%) in the NINLARO regimen and 9 patients (15%) in the placebo regimen.</p><p><strong><u><em>Hepatic impairment</em></u></strong></p><p>No dose adjustment of NINLARO is required for patients with mild hepatic impairment (total bilirubin</p><p>&le; upper limit of normal (ULN) and aspartate aminotransferase (AST) &gt; ULN or total bilirubin</p><p>&gt; 1-1.5 x ULN and any AST). The reduced dose of 3 mg is recommended in patients with moderate (total bilirubin &gt; 1.5-3 x ULN) or severe (total bilirubin &gt; 3 x ULN) hepatic impairment (see section 5.2).</p><p><strong><u><em>Renal impairment</em></u></strong></p><p>No dose adjustment of NINLARO is required for patients with mild or moderate renal impairment (creatinine clearance &ge; 30 mL/min). The reduced dose of 3 mg is recommended in patients with severe renal impairment (creatinine clearance &lt; 30 mL/min) or end-stage renal disease (ESRD) requiring dialysis. NINLARO is not dialyzable and, therefore, can be administered without regard to the timing of dialysis (see section 5.2).</p><p>Refer to the lenalidomide SmPC for dosing recommendations in patients with renal impairment.</p><p><em>Paediatric population</em></p><p>The safety and efficacy of NINLARO in children below 18 years of age have not been established. No data are available.</p><p><strong><u>Method of administration</u></strong></p><p>NINLARO is for oral use.</p><p>NINLARO should be taken at approximately the same time on days 1, 8, and 15 of each treatment cycle at least 1 hour before or at least 2 hours after food (see section 5.2). The capsule should be swallowed whole with water. It should not be crushed, chewed, or opened (see section 6.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

As NINLARO is administered in combination with lenalidomide and dexamethasone, refer to the SmPC for these medicinal products for additional contraindications.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>As NINLARO is administered in combination with lenalidomide and dexamethasone, refer to the SmPC for these medicinal products for additional special warnings and precautions for use.</p><p><u>Thrombocytopenia</u></p><p>Thrombocytopenia has been reported with NINLARO (see section 4.8) with platelet nadirs typically occurring between Days 14-21 of each 28-day cycle and recovery to baseline by the start of the next cycle (see section 4.8).</p><p>Platelet counts should be monitored at least monthly during NINLARO treatment. More frequent monitoring should be considered during the first three cycles as per the lenalidomide SmPC. Thrombocytopenia can be managed with dose modifications (see section 4.2) and platelet transfusions as per standard medical guidelines.</p><p><u>Gastrointestinal toxicities</u></p><p>Diarrhoea, constipation, nausea and vomiting have been reported with NINLARO, occasionally requiring use of antiemetic and antidiarrhoeal medicinal products and supportive care (see</p><p>section 4.8). The dose should be adjusted for severe (Grade 3-4) symptoms (see section 4.2). In case of severe gastrointestinal events, monitoring of serum potassium level is recommended.</p><p><u>Peripheral neuropathy</u></p><p>Peripheral neuropathy has been reported with NINLARO (see section 4.8). The patient should be monitored for symptoms of peripheral neuropathy. Patients experiencing new or worsening peripheral neuropathy may require dose modification (see section 4.2).</p><p><u>Peripheral oedema</u></p><p>Peripheral oedema has been reported with NINLARO (see section 4.8). The patient should be evaluated for underlying causes and provide supportive care, as necessary. The dose of dexamethasone</p><p>should be adjusted per its prescribing information or NINLARO for Grade 3 or 4 symptoms (see section 4.2).</p><p><u>Cutaneous reactions</u></p><p>Rash has been reported with NINLARO (see section 4.8). Rash should be managed with supportive care or with dose modification if Grade 2 or higher (see section 4.2)<em>.</em></p><p><u>Hepatotoxicity</u></p><p>Drug-induced liver injury, hepatocellular injury, hepatic steatosis, hepatitis cholestatic and hepatotoxicity have been uncommonly reported with NINLARO (see section 4.8). Hepatic enzymes should be monitored regularly and the dose should be adjusted for Grade 3 or 4 symptoms (see section 4.2)<em>.</em></p><p><u>Pregnancy</u></p><p>Women should avoid becoming pregnant while being treated with NINLARO. If NINLARO is used during pregnancy or if the patient becomes pregnant while taking NINLARO, the patient should be apprised of the potential hazard to the foetus.</p><p>Women of childbearing potential must use highly effective contraception while taking NINLARO and for 90 days after stopping treatment (see sections 4.5 and 4.6). Women using hormonal contraceptives should additionally use a barrier method of contraception<strong>.</strong></p><p><u>Posterior reversible encephalopathy syndrome</u></p><p>Posterior reversible encephalopathy syndrome (PRES) has occurred in patients receiving NINLARO. PRES is a rare, reversible, neurological disorder which can present with seizure, hypertension, headache, altered consciousness, and visual disturbances. Brain imaging, preferably Magnetic Resonance Imaging, is used to confirm the diagnosis. In patients developing PRES, discontinue NINLARO.</p><p><u>Strong CYP3A inducers</u></p><p>Strong inducers may reduce the efficacy of NINLARO, therefore the concomitant use of strong CYP3A inducers such as carbamazepine, phenytoin, rifampicin and St. John&rsquo;s Wort (<em>Hypericum perforatum</em>), should be avoided (see sections 4.5 and 5.2). Closely monitor patients for disease control if co-administration with a strong CYP3A inducer cannot be avoided.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pharmacokinetic interactions</u></p><p><em><u>CYP inhibitors</u></em></p><p>Co-administration of ixazomib with clarithromycin, a strong CYP3A inhibitor, did not result in a clinically meaningful change in the systemic exposure of ixazomib. Ixazomib C<sub>max</sub> was decreased by 4% and AUC was increased by 11%. Therefore, no dose modification is required for ixazomib with co-administration of strong CYP3A inhibitors.</p><p>Co-administration of ixazomib with strong CYP1A2 inhibitors did not result in a clinically meaningful change in the systemic exposure of ixazomib based on the results of a population pharmacokinetic (PK) analysis. Therefore, no dose modification is required for ixazomib with co-administration of strong CYP1A2 inhibitors.</p><p><em><u>CYP inducers</u></em></p><p>Co-administration of ixazomib with rifampicin decreased ixazomib C<sub>max</sub> by 54% and AUC by 74%. Therefore, co-administration of strong CYP3A inducers with ixazomib is not recommended (see section 4.4).</p><p><em><u>Effect of ixazomib on other medicinal products</u></em></p><p>Ixazomib is not a reversible or a time-dependent inhibitor of CYPs 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, or 3A4/5. Ixazomib did not induce CYP1A2, CYP2B6, and CYP3A4/5 activity or corresponding immunoreactive protein levels. Ixazomib is not expected to produce drug-drug interactions via CYP inhibition or induction.</p><p><em><u>Transporter-based interactions</u></em></p><p>Ixazomib is a low affinity substrate of P-gp. Ixazomib is not a substrate of BCRP, MRP2 or hepatic OATPs. Ixazomib is not an inhibitor of P-gp, BCRP, MRP2, OATP1B1, OATP1B3, OCT2, OAT1, OAT3, MATE1, or MATE2-K. Ixazomib is not expected to cause transporter-mediated drug-drug interactions.</p><p><u>Oral contraceptives</u></p><p>When NINLARO is administered together with dexamethasone, which is known to be a weak to moderate inducer of CYP3A4 as well as other enzymes and transporters, the risk for reduced efficacy of oral contraceptives needs to be considered. Women using hormonal contraceptives should additionally use a barrier method of contraception.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>As NINLARO is administered in combination with lenalidomide and dexamethasone, refer to the SmPC for these medicinal products for additional information on fertility, pregnancy and lactation.</p><p><u>Women of childbearing potential/Contraception in males and females</u></p><p>Male and female patients who are able to have children must use effective contraceptive measures during and for 90 days following treatment. NINLARO is not recommended in women of childbearing potential not using contraception.</p><p>When NINLARO is administered together with dexamethasone, which is known to be a weak to moderate inducer of CYP3A4 as well as other enzymes and transporters, the risk for reduced efficacy of oral contraceptives needs to be considered. Therefore, women using oral hormonal contraceptives should additionally use a barrier method of contraception.</p><p><u>Pregnancy</u></p><p>NINLARO is not recommended during pregnancy as it can cause foetal harm when administered to a pregnant woman. Therefore, women should avoid becoming pregnant while being treated with NINLARO.</p><p>There are no data for the use of NINLARO in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3).</p><p>NINLARO is given in combination with lenalidomide. Lenalidomide is structurally related to thalidomide. Thalidomide is a known human teratogenic active substance that causes severe</p><p>life-threatening birth defects. If lenalidomide is taken during pregnancy, a teratogenic effect in humans is expected. The conditions of the Pregnancy Prevention Programme for lenalidomide must be fulfilled for all patients unless there is reliable evidence that the patient does not have childbearing potential.</p><p>Please refer to the current lenalidomide SmPC. <u>Breast-feeding</u></p><p>It is unknown whether NINLARO or its metabolites are excreted in human milk. No animal data are available. A risk to newborns/infants cannot be excluded and therefore breast-feeding should be discontinued.</p><p>NINLARO will be given in combination with lenalidomide and breast-feeding should be stopped because of the use of lenalidomide.</p><p><u>Fertility</u></p><p>Fertility studies have not been conducted with NINLARO (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NINLARO has minor influence on the ability to drive or use machines. Fatigue and dizziness have been observed in clinical trials. Patients should be advised not to drive or operate machines if they experience any of these symptoms.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>As NINLARO is administered in combination with lenalidomide and dexamethasone, refer to the SmPC for these medicinal products for additional undesirable effects.</p><p><u>Summary of the safety profile</u></p><p>The data presented below is the pooled safety data from the pivotal, Phase 3, global C16010 study (n=720) and the double-blind, placebo-controlled C16010 China Continuation Study (n=115). The most frequently reported adverse reactions (&ge; 20%) across 417 patients treated within the NINLARO regimen and 418 patients within the placebo regimen were diarrhoea (39% vs. 32%), thrombocytopenia (33% vs. 21%), neutropenia (33% vs. 30%), constipation (30% vs. 22%), peripheral</p><p>neuropathy (25% vs. 20%), nausea (23% vs. 18%), peripheral oedema (23% vs. 17%), vomiting (20% vs. 10%) and upper respiratory tract infection (21% vs. 16%). Serious adverse reactions reported in</p><p>&ge; 2% of patients included thrombocytopenia (2%) and diarrhoea (2%).</p><p><u>Tabulated list of adverse reactions</u></p><p>The following convention is used for the classification of the frequency of an adverse drug reaction (ADR): very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000); not known (cannot be estimated from the available data). Within each system organ class, the adverse drug reactions are ranked by frequency, with the most frequent reactions first. Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p>Table 3: Adverse reactions in patients treated with NINLARO in combination with lenalidomide and dexamethasone (all grades, grade 3 and grade 4)</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class /</strong></p><p><strong>Adverse reaction</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reactions</strong></p><p><strong>(all grades)</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3 adverse</strong></p><p><strong>reactions</strong></p></td><td style="vertical-align:top"><p><strong>Grade 4 adverse</strong></p><p><strong>reactions</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Upper respiratory tract</p><p>infection</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Herpes zoster</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia*</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Neutropenia*</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Peripheral neuropathies*</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Diarrhoea</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rash*</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Back pain</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Oedema peripheral</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><strong>Note: Adverse drug reactions included as preferred terms are based on MedDRA version 16.0.</strong></p><p>*Represents a pooling of preferred terms</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p><em><u>Discontinuations</u></em></p><p>For each adverse reaction, one or more of the three medicinal products was discontinued in &le; 1% of patients in the NINLARO regimen.</p><p><em><u>Thrombocytopenia</u></em></p><p>Three percent of patients in the NINLARO regimen and 1% of patients in the placebo regimen had a platelet count &le; 10,000/mm<sup>3</sup> during treatment. Less than 1% of patients in both regimens had a platelet count &le; 5,000/mm<sup>3</sup> during treatment. Thrombocytopenia resulted in discontinuation of one or more of the three medicinal products in &lt; 1% of patients in the NINLARO regimen and 1% of patients in the placebo regimen. Thrombocytopenia did not result in an increase in haemorrhagic events or platelet transfusions.</p><p><em><u>Gastrointestinal toxicities</u></em></p><p>Diarrhoea resulted in discontinuation of one or more of the three medicinal products in 1% of patients in the NINLARO regimen and &lt; 1% of patients in the placebo regimen.</p><p><em><u>Rash</u></em></p><p>Rash occurred in 18% of patients in the NINLARO regimen compared to 10% of patients in the placebo regimen. The most common type of rash reported in both regimens was maculo-papular and macular rash. Grade 3 rash was reported in 2% of patients in the NINLARO regimen compared to 1% of patients in the placebo regimen. Rash resulted in discontinuation of one or more of the three medicinal products in &lt; 1% of patients in both regimens.</p><p><em><u>Peripheral neuropathy</u></em></p><p>Peripheral neuropathy occurred in 25% of patients in the NINLARO regimen compared to 20% of patients in the placebo regimen. Grade 3 adverse reactions of peripheral neuropathy were reported in 2% of patients in both regimens. The most commonly reported reaction was peripheral sensory neuropathy (16% and 12% in the NINLARO and placebo regimen, respectively). Peripheral motor neuropathy was not commonly reported in either regimen (&lt; 1%). Peripheral neuropathy resulted in discontinuation of one or more of the three medicinal products in 1% of patients in the NINLARO regimen compared to &lt;1% of patients in the placebo regimen.</p><p><em><u>Eye Disorders</u></em></p><p>Eye disorders were reported with many different preferred terms but in aggregate, the frequency was 24% in patients in the NINLARO regimen and 15% of patients in the placebo regimen. The most common adverse reactions were blurred vision (5% in the NINLARO regimen and 4% in the placebo regimen), dry eye (4% in the NINLARO regimen and 1% in the placebo regimen), conjunctivitis (5% in the NINLARO regimen and 1% in the placebo regimen) and cataract (4% in the NINLARO regimen and 5% in the placebo regimen). Grade 3 adverse reactions were reported in 2% of patients in both regimens.</p><p><em><u>Other adverse reactions</u></em></p><p>Outside of the Phase 3 study, the following serious adverse reactions were rarely reported: acute febrile neutrophilic dermatosis (Sweet&rsquo;s syndrome), Stevens-Johnson syndrome, transverse myelitis, posterior reversible encephalopathy syndrome, tumour lysis syndrome and thrombotic thrombocytopenic purpura.</p><p>In the pooled dataset from the pivotal, Phase 3, global C16010 study (n=720) and the double-blind, placebo-controlled, C16010 China Continuation Study (n=115), the following adverse reactions occurred with a similar rate between the NINLARO and placebo regimens: fatigue (26% vs. 24%), decreased appetite (12% vs. 9%), hypotension (4% each), heart failure<sup>&dagger;</sup> ( 3% each), arrhythmia<sup>&dagger;</sup> (12% vs. 11%), and liver impairment including enzyme changes<sup>&dagger;</sup> (8% vs. 6%).</p><p>The frequency of severe (Grade 3-4) events of hypokalaemia was higher in the NINLARO regimen (5%) than the placebo regimen (&lt;1%).</p><p>Fungal and viral pneumonia resulting in fatal outcome were rarely reported in patients given the NINLARO, lenalidomide and dexamethasone combination.</p><p><u>&dagger; </u><u>Standardised MedDRA Queries (SMQs)</u></p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national pharmacovigilance and drug safety centre (NPC).</p><p><strong>To report any side effect(s):</strong></p><p><em>Saudi Arabia</em></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p><strong>The National Pharmacovigilance and Drug Safety Centre (NPC)</strong></p><p>Fax: +966-11-205-7662</p><p>Call NPC at +966-11-2038222</p><p>Exts: 2317-2356-2353-2354-2334-2340.</p><p>Toll free phone: 8002490000 E-mail: npc.drug@sfda.gov.sa Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p><strong><em>Other GCC States</em></strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p>Please contact the relevant competent authority.</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no known specific antidote for NINLARO overdose. Clinical data is limited but doses up to 12 mg have been reported in the randomized controlled trial. In the event of an overdose, monitor the patient for adverse reactions (section 4.8) and provide appropriate supportive care.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antineoplastic agents, other antineoplastic agents, ATC code: L01XX50 <u>Mechanism of action</u></p><p>Ixazomib citrate, a prodrug, is a substance that rapidly hydrolyses under physiological conditions to its biologically active form, ixazomib.</p><p>&nbsp;</p><p>Ixazomib is an oral, highly selective and reversible proteasome inhibitor. Ixazomib preferentially binds and inhibits the chymotrypsin-like activity of the beta 5 subunit of the 20S proteasome.</p><p>&nbsp;</p><p>Ixazomib induced apoptosis of several tumour cell types <em>in vitro</em>. Ixazomib demonstrated <em>in vitro </em>cytotoxicity against myeloma cells from patients who had relapsed after multiple prior therapies, including bortezomib, lenalidomide, and dexamethasone. The combination of ixazomib and lenalidomide demonstrated synergistic cytotoxic effects in multiple myeloma cell lines. <em>In vivo</em>, ixazomib demonstrated antitumour activity in various tumour xenograft models, including models of multiple myeloma. <em>In vitro</em>, ixazomib affected cell types found in the bone marrow microenvironment including vascular endothelial cells, osteoclasts and osteoblasts.</p><p>&nbsp;</p><p><u>Cardiac electrophysiology</u></p><p>&nbsp;</p><p>Ixazomib did not prolong the QTc interval at clinically relevant exposures based on the results of a pharmacokinetic-pharmacodynamic analysis of data from 245 patients. At the 4 mg dose,</p><p>mean change from baseline in QTcF was estimated to be 0.07 msec (90% CI; -0.22, 0.36) from the model based analysis. There was no discernible relationship between ixazomib concentration and the RR interval suggesting no clinically meaningful effect of ixazomib on heart rate.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p>The efficacy and safety of NINLARO in combination with lenalidomide and dexamethasone was evaluated in an international randomized, double-blind, placebo-controlled, multicenter Phase 3 superiority study (C16010) in patients with relapsed and/or refractory multiple myeloma who had received at least one prior therapy. A total of 722 patients (intent-to-treat [ITT] population) were randomized in a 1:1 ratio to receive either the combination of NINLARO, lenalidomide, and dexamethasone (N=360; NINLARO regimen) or placebo, lenalidomide and dexamethasone (N=362; placebo regimen) until disease progression or unacceptable toxicity. Patients enrolled in the trial had multiple myeloma that was refractory, including primary refractory, had relapsed after</p><p>prior therapy, or had relapsed and was refractory to any prior therapy. Patients that changed therapies</p><p>&nbsp;</p><p>prior to disease progression were eligible for enrolment, as well as those with controlled cardiovascular conditions. The Phase 3 study excluded patients who were refractory to lenalidomide or proteasome inhibitors and patients who received more than three prior therapies. For the purposes of this study, refractory disease was defined as disease progression on treatment or progression within 60 days after the last dose of lenalidomide or a proteasome inhibitor. As data are limited in these patients, a careful risk-benefit assessment is recommended before initiating the NINLARO regimen.</p><p>&nbsp;</p><p>Thromboprophylaxis was recommended for all patients in both treatment groups according to the lenalidomide SmPC. Concomitant medications, such as antiemetic, antiviral, and antihistamine medications were given to patients at the physician&#39;s discretion as prophylaxis and/or management of symptoms.</p><p>&nbsp;</p><p>Patients received NINLARO 4 mg or placebo on Days 1, 8, and 15 plus lenalidomide (25 mg) on Days 1 through 21 and dexamethasone (40 mg) on Days 1, 8, 15, and 22 of a 28-day cycle. Patients with renal impairment received a starting dose of lenalidomide according to its SmPC. Treatment continued until disease progression or unacceptable toxicities.</p><p>&nbsp;</p><p>The baseline demographics and disease characteristics were balanced and comparable between the study regimens. The median age was 66 years, range 38-91 years; 58% of patients were older than 65 years. Fifty seven percent of patients were male. Eighty five percent of the population was White, 9% Asian and 2% Black. Ninety three percent of patients had an ECOG performance status of 0-1 and 12% had baseline ISS stage III disease (N=90). Twenty five percent of patients had a creatinine clearance of &lt; 60 mL/min. Twenty three percent of patients had light chain disease and 12% of patients had measurable disease by free light chain assay only. Nineteen percent had high-risk cytogenetic abnormalities (del[17], t[4;14], t[14;16]) (N=137), 10% had del(17) (N=69) and 34% had 1q amplification (1q21) (N=247). Patients received one to three prior therapies (median of 1) including prior treatment with bortezomib (69%), carfilzomib (&lt;1%), thalidomide (45%), lenalidomide (12%), melphalan (81%). Fifty seven percent of patients had undergone prior stem cell transplantation. Seventy seven percent of patients relapsed after prior therapies and 11% were refractory to prior therapies. Primary refractory, defined as best response of stable disease or disease progression on all prior therapies, was documented in 6% of patients.</p><p>&nbsp;</p><p>The primary endpoint was progression-free survival (PFS) according to the 2011 International Myeloma Working Group (IMWG) Consensus Uniform Response Criteria as assessed by a blinded independent review committee (IRC) based on central laboratory results. Response was assessed every 4 weeks until disease progression. At the primary analysis (median follow up of 14.7 months and a median of 13 cycles), PFS was statistically significantly different between the treatment arms. PFS results are summarized in Table 4 and Figure 1. The improvement in PFS in the NINLARO regimen was supported by improvements in overall response rate.</p><p>&nbsp;</p><p>Table 4: Progression Free Survival and Response Results in Multiple Myeloma Patients Treated with NINLARO or Placebo in Combination with Lenalidomide and Dexamethasone (Intent-to- Treat Population)</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>NINLARO + Lenalidomide and Dexamethasone</p><p>(N = 360)</p></td><td style="vertical-align:top"><p>Placebo + Lenalidomide and Dexamethasone</p><p>(N = 362)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Progression-Free Survival</strong></p></td></tr><tr><td style="vertical-align:top"><p>Events, n (%)</p></td><td style="vertical-align:top"><p>129 (36)</p></td><td style="vertical-align:top"><p>157 (43)</p></td></tr><tr><td style="vertical-align:top"><p>Median (months)</p></td><td style="vertical-align:top"><p>20.6</p></td><td style="vertical-align:top"><p>14.7</p></td></tr><tr><td style="vertical-align:top"><p>p-value*</p></td><td colspan="2" style="vertical-align:top"><p>0.012</p></td></tr><tr><td style="vertical-align:top"><p>Hazard Ratio<sup>&dagger;</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.74</p></td></tr><tr><td style="vertical-align:top"><p>(95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>(0.59, 0.94)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Overall Response Rate</strong><sup>&Dagger;</sup><strong>, n (%)</strong></p></td><td style="vertical-align:top"><p>282 (78.3)</p></td><td style="vertical-align:top"><p>259 (71.5)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Response Category, n (%)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Complete Response</p></td><td style="vertical-align:top"><p>42 (11.7)</p></td><td style="vertical-align:top"><p>24 (6.6)</p></td></tr><tr><td style="vertical-align:top"><p>Very Good Partial Response</p></td><td style="vertical-align:top"><p>131 (36.4)</p></td><td style="vertical-align:top"><p>117 (32.3)</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Partial Response</p></td><td style="vertical-align:top"><p>109 (30.3)</p></td><td style="vertical-align:top"><p>118 (32.6)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Time to Response, months</strong></p></td></tr><tr><td style="vertical-align:top"><p>Median</p></td><td style="vertical-align:top"><p>1.1</p></td><td style="vertical-align:top"><p>1.9</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Duration of Response</strong><sup>&sect;</sup><strong>, months</strong></p></td></tr><tr><td style="vertical-align:top"><p>Median</p></td><td style="vertical-align:top"><p>20.5</p></td><td style="vertical-align:top"><p>15.0</p></td></tr></tbody></table><p>*P-value is based on the stratified log-rank test.</p><p>&dagger;Hazard ratio is based on a stratified Cox&rsquo;s proportional hazard regression model. A hazard ratio less than 1</p><p>indicates an advantage for the NINLARO regimen.</p><p>&Dagger;ORR = CR+VGPR+PR</p><p>&sect;Based on responders in the response-evaluable population</p><p>&nbsp;</p><p>A planned interim analysis for overall survival (OS) at a median follow up of 23 months was conducted with 35% of the required number of deaths for final OS analysis in the ITT population; there were 81 deaths in the NINLARO regimen and 90 deaths in the placebo regimen. Median overall survival was not reached in either regimen. At this analysis, estimated median PFS was 20 months in the NINLARO regimen and 15.9 months in the placebo regimen (HR=0.82 [95% CI (0.67, 1.0)]) in the ITT population.</p><p>A randomized, double-blind, placebo-controlled Phase 3 study was conducted in China (N=115) with a similar study design and eligibility criteria. Many of the patients enrolled in the study had advanced disease with Durie-Salmon Stage III (69%) at initial diagnosis and a treatment history of receiving at least 2 prior therapies (60%) and being thalidomide refractory (63%). At the primary analysis (median follow up of 8 months and a median of 6 cycles), the median PFS was 6.7 months in the NINLARO regimen compared to 4 months in the placebo regimen (p-value=0.035, HR=0.60). At the final analysis for OS at a median follow up of 19.8 months, OS was improved for patients treated in the ixazomib regimen compared with placebo [p-value=0.0014, HR=0.42, 95% CI: 0.242, 0.726 ]).</p><p>As multiple myeloma is a heterogeneous disease, benefit may vary across subgroups in the Phase 3 study (C16010) (see Figure 2).</p><p>In the Phase 3 study (C16010), 10 patients (5 in each treatment regimen) had severe renal impairment at baseline. Of the 5 patients in the NINLARO regimen, one patient had a confirmed partial response and 3 confirmed stable disease (however 2 were unconfirmed partial response and 1 was an unconfirmed very good partial response). Of the 5 patients in the placebo regimen, 2 had a confirmed very good partial response.</p><p>Quality of life as assessed by global health scores (EORTC QLQ-C30 and MY-20) was maintained during treatment and was similar in both treatment regimens in the Phase 3 study (C16010).</p><p><u>Paediatric population</u></p><p>The European Medicines Agency has waived the obligation to submit the results of studies with NINLARO in all subsets of the paediatric population in multiple myeloma (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>After oral administration, peak plasma concentrations of ixazomib were achieved at approximately one hour after dosing. The mean absolute oral bioavailability is 58%. Ixazomib AUC increases in a dose proportional manner over a dose range of 0.2-10.6 mg.</p><p>Administration with a high-fat meal decreased ixazomib AUC by 28% compared with administration after an overnight fast (see section 4.2).</p><p><u>Distribution</u></p><p>Ixazomib is 99% bound to plasma proteins and distributes into red blood cells with a blood-to-plasma AUC ratio of 10. The steady-state volume of distribution is 543 L.</p><p><u>Biotransformation</u></p><p>After oral administration of a radiolabeled dose, 70% of total drug-related material in plasma was accounted for by ixazomib. Metabolism by multiple CYP enzymes and non-CYP proteins is expected to be the major clearance mechanism for ixazomib. At clinically relevant ixazomib concentrations,</p><p><em>in vitro </em>studies using human cDNA-expressed cytochrome P450 isozymes indicate that no specific CYP isozyme predominantly contributes to ixazomib metabolism and non-CYP proteins contribute to overall metabolism. At concentrations exceeding those observed clinically, ixazomib was metabolized by multiple CYP isoforms with estimated relative contributions of 3A4 (42.3%), 1A2 (26.1%),</p><p>2B6 (16.0%), 2C8 (6.0%), 2D6 (4.8%), 2C19 (4.8%) and 2C9 (&lt; 1%).</p><p><u>Elimination</u></p><p>Ixazomib exhibits a multi-exponential disposition profile. Based on a population PK analysis, systemic clearance (CL) was approximately 1.86 L/hr with inter-individual variability of 44%. The terminal half-life (t<sub>1/2</sub>) of ixazomib was 9.5 days. Approximately 2-fold accumulation in AUC was observed with weekly oral dosing on Day 15.</p><p><em><u>Excretion</u></em></p><p>After administration of a single oral dose of <sup>14</sup>C-ixazomib to 5 patients with advanced cancer, 62% of the administered radioactivity was excreted in urine and 22% in the faeces. Unchanged ixazomib accounted for &lt; 3.5% of the administered dose recovered in urine.</p><p><u>Special populations</u></p><p><em><u>Hepatic impairment</u></em></p><p>The PK of ixazomib is similar in patients with normal hepatic function and in patients with mild hepatic impairment (total bilirubin &le; ULN and AST &gt; ULN or total bilirubin &gt; 1-1.5 x ULN and any AST) based on the results of a population PK analysis.</p><p>The PK of ixazomib was characterized in patients with normal hepatic function at 4 mg (N=12), moderate hepatic impairment at 2.3 mg (total bilirubin &gt; 1.5-3 x ULN, N=13) or severe hepatic impairment at 1.5 mg (total bilirubin &gt; 3 x ULN, N=18). Unbound dose-normalized AUC was 27% higher in patients with moderate or severe hepatic impairment as compared to patients with normal hepatic function (see section 4.2).</p><p><em><u>Renal impairment</u></em></p><p>The PK of ixazomib is similar in patients with normal renal function and in patients with mild or moderate renal impairment (creatinine clearance &ge; 30 mL/min) based on the results of a population PK analysis.</p><p>The PK of ixazomib was characterized at a dose of 3 mg in patients with normal renal function (creatinine clearance &ge; 90 mL/min, N=18), severe renal impairment (creatinine clearance</p><p>&lt; 30 mL/min, N=14), or ESRD requiring dialysis (N=6). Unbound AUC was 38% higher in patients with severe renal impairment or ESRD requiring dialysis as compared to patients with normal renal function. Pre- and post-dialyzer concentrations of ixazomib measured during the haemodialysis session were similar, suggesting that ixazomib is not dialyzable (see section 4.2).</p><p><em><u>Age, gender, race</u></em></p><p>There was no clinically meaningful effect of age (23-91 years), sex, body surface area (1.2-2.7 m<sup>2</sup>), or race on the clearance of ixazomib based on the results of a population PK analysis. The mean AUC was 35% higher in Asian patients; however, there was overlap in the AUC of ixazomib across White and Asian patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Mutagenicity</u></p><p>Ixazomib was not mutagenic in a bacterial reverse mutation assay (Ames assay) or clastogenic in a bone marrow micronucleus assay in mice. Ixazomib was positive in an <em>in vitro </em>clastogenicity test in human peripheral blood lymphocytes. However, ixazomib was negative in an <em>in vivo </em>comet assay in mice, in which percent tail DNA was assessed in the stomach and liver. Therefore, the weight of evidence indicates that NINLARO is not considered to present a genotoxic risk.</p><p><u>Reproductive and embryo-foetal development</u></p><p>Ixazomib caused embryo-foetal toxicity in pregnant rats and rabbits only at maternally toxic doses and at exposures that were slightly higher than those observed in patients receiving the recommended dose. Studies of fertility and early embryonic development and pre- and post-natal toxicology were not conducted with ixazomib, but evaluation of reproductive tissues was conducted in the general toxicity studies. There were no effects due to ixazomib treatment on male or female reproductive organs in studies up to 6-months duration in rats and up to 9-months duration in dogs.</p><p><u>Animal toxicology and/or pharmacology</u></p><p>In multi-cycle repeated-dose toxicity studies conducted in rats and dogs, the principal target organs included the gastrointestinal tract, lymphoid tissues, and the nervous system. In the 9-month study (10 cycles) in dogs orally administered with a dosing schedule mimicking the clinical regimen</p><p>(28-day cycle), microscopic neuronal effects were generally minimal in nature and only observed at</p><p>0.2 mg/kg (4 mg/m<sup>2</sup>). The majority of target organ findings demonstrated partial to full recovery following discontinuation of treatment, with the exception of neuronal findings in the lumbar dorsal root ganglion and dorsal column.</p><p>Following oral administration, a tissue distribution study in rats revealed that the brain and spinal cord were amongst the tissues with the lowest levels, suggesting that the penetration of ixazomib through the blood-brain barrier appears to be limited. However, the relevance to humans is unknown.</p><p>Non-clinical safety pharmacology studies both <em>in vitro </em>(on hERG channels) and <em>in vivo </em>(in telemetered dogs following single oral administration) demonstrated no effects of ixazomib on cardiovascular or respiratory functions at AUC more than 8-fold higher than the clinical value.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>NINLARO 2.3 mg hard capsules</u></p><p><em><u>Capsule contents</u> </em></p><p>Microcrystalline cellulose Magnesium stearate</p><p>Talc</p><p><em><u>Capsule shell</u></em></p><p>Gelatin</p><p>Titanium dioxide (E171) Red iron oxide (E172)</p><p><em><u>Printing ink</u> </em></p><p>Shellac Propylene glycol</p><p>Potassium hydroxide Black iron oxide (E172)</p><p><u>NINLARO 3 mg hard capsules</u></p><p><em><u>Capsule contents</u> </em></p><p>Microcrystalline cellulose Magnesium stearate</p><p>Talc</p><p><em><u>Capsule shell</u></em></p><p>Gelatin</p><p>Titanium dioxide (E171) Black iron oxide (E172)</p><p><em><u>Printing ink</u></em></p><p>Shellac Propylene glycol</p><p>Potassium hydroxide Black iron oxide (E172)</p><p><u>NINLARO 4 mg hard capsules</u></p><p><em><u>Capsule contents</u></em><em> </em></p><p>Microcrystalline cellulose</p><p>Magnesium stearate</p><p>Talc</p><p><em><u>Capsule shell</u></em></p><p>Gelatin</p><p>Titanium dioxide (E171)</p><p>Yellow iron oxide (E172)</p><p>Red iron oxide (E172)</p><p><em><u>Printing ink</u></em><em> </em></p><p>Shellac Propylene glycol</p><p>Potassium hydroxide</p><p>Black iron oxide (E172)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C. Do not freeze.</p><p>Store in the original package in order to protect from moisture</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PVC-Aluminium /Aluminium blister sealed inside a wallet pack containing one capsule.</p><p>Three single blister wallet packs are packaged in one carton.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NINLARO is cytotoxic. The capsule should not be removed until just prior to dosing. The capsules should not be opened or crushed. Direct contact with the capsule contents should be avoided. In case of capsule breakage, avoid raising dust during clean-up. If contact occurs, wash thoroughly with soap and water.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Takeda Pharma A/S Dybendal Alle 10
2630 Taastrup Denmark
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                July 2017.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>